MERS

Raffles Medical Group upgraded to 'buy' on improved risk-reward: Maybank - THE EDGE SINGAPORE

Broker's Calls

Raffles Medical Group upgraded to 'buy' on improved risk-reward: Maybank

Following a share price correction, Maybank Kim Eng Research analyst Lai Gene Lih has upgraded Raffles Medical Group to “buy”.

This new anti-viral drug could beat Ebola, SARS, H5N1 Avian Bird Flu, and more

SINGAPORE (Feb 28): Singapore eDevelopment (SeD) announced Wednesday that its biomedical subsidiary, Global BioLife Inc., has completed the Zaire Ebola virus research portion for the study of a new anti-viral drug called LB2.
×